ROVI.MC · MCE · Healthcare
Laboratorios Farmaceuticos Rovi, S.A.
Also onConsensus Drift
Implied value per share
EUR 46.13
Market price
EUR 57.65
Implied upside
-20.0%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (EUR). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | EUR 720.3m | EUR 697.8m | EUR 676.0m | EUR 654.9m | EUR 634.5m | -3.1% |
| EBIT | EUR 191.5m | EUR 185.5m | EUR 179.7m | EUR 174.1m | EUR 168.7m | -3.1% |
| NOPAT | EUR 147.7m | EUR 143.1m | EUR 138.6m | EUR 134.3m | EUR 130.1m | -3.1% |
| Add depreciation & amortisation | EUR 24.3m | EUR 23.5m | EUR 22.8m | EUR 22.1m | EUR 21.4m | -3.1% |
| Less capital expenditure | EUR -54.4m | EUR -52.7m | EUR -51.0m | EUR -49.5m | EUR -47.9m | -3.1% |
| Less increase in working capital | EUR 5.2m | EUR 5.1m | EUR 4.9m | EUR 4.7m | EUR 4.6m | +3.1% |
| Free cashflow to firm | EUR 122.8m | EUR 119.0m | EUR 115.3m | EUR 111.7m | EUR 108.2m | -3.1% |
| Discount factor | 0.9658 | 0.9009 | 0.8404 | 0.7839 | 0.7312 | - |
| Present value | EUR 118.6m | EUR 107.2m | EUR 96.9m | EUR 87.5m | EUR 79.1m | -9.6% |
| Present Value Of The Forecast | EUR 489.4m | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 4.20% | USD assumption - no free live source available for this market (assumption) |
| Equity risk premium | 6.50% | Market assumption |
| Beta | 0.487 | Reported 0.235, pulled toward 1.0 (Blume) |
| Cost of equity | 7.37% | Risk-free + beta x equity risk premium |
| Cost of debt | 4.20% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | EUR 2.9bn | 96.0% of capital |
| Total debt | EUR 121.7m | 4.0% of capital, book value as a proxy |
| Tax rate | 22.9% | Effective, capped at statutory |
| WACC | 7.20% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
79% of EV
- Forecast FCFF, final year
- EUR 108.2m
- Capex at depreciation, working capital in reinvestment
- EUR 132.2m
- Less reinvestment at g/ROIC (10.1% of NOPAT)
- EUR -13.3m
- Capitalised
- EUR 118.9m
- ROIC (reported)
- 24.8%
- Terminal value, undiscounted
- EUR 2.6bn
- Terminal value, discounted
- EUR 1.9bn
- Enterprise value
- EUR 2.4bn
- Less net debt
- EUR 23.7m
- Equity value
- EUR 2.4bn
Exit at 13.7x EBITDA
80% of EV
- Terminal value, undiscounted
- EUR 2.6bn
- Terminal value, discounted
- EUR 1.9bn
- Enterprise value
- EUR 2.4bn
- Less net debt
- EUR 23.7m
- Equity value
- EUR 2.4bn
Spread between methods: 1%.
Sensitivity
Value per share (EUR) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 5.20% | 62.47 | 69.72 | 79.62 | 94.01 | 116.80 |
| 6.20% | 49.27 | 53.27 | 58.35 | 65.01 | 74.10 |
| 7.20% | 40.69 | 43.15 | 46.13 | 49.80 | 54.45 |
| 8.20% | 34.68 | 36.29 | 38.19 | 40.43 | 43.15 |
| 9.20% | 30.23 | 31.34 | 32.61 | 34.09 | 35.81 |
Outlined: this model. Green text: above today's price of 57.65. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | -3.1% | 2.0% | +5.1pp |
| EBIT margin | 26.6% | 33.0% | +6.4pp |
| Discount rate | 7.2% | 6.3% | -1.0pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.